Company Overview
Fredun Pharmaceuticals Limited (BSE: 539730) demonstrated strong financial performance in FY26 while undertaking significant corporate actions through its 39th Annual General Meeting.
Financial Performance
Fredun Pharmaceuticals reported outstanding standalone results for FY26 with net profit surging 60% YoY to ₹3,320.69 lakhs and revenue growing 40% to ₹63,332.65 lakhs. Consolidated net profit attributable to owners increased 69% to ₹3,279.00 lakhs. Key profitability metrics improved significantly with Return on Equity reaching 21% (from 15% in FY25) and net profit ratio expanding to 10.58% (from 4.56%). The company maintained strong operational efficiency with trade receivables turnover improving to 4.69 times and inventory turnover to 1.89 times.
Capital Structure & Corporate Actions
The Board recommended a 7% dividend (₹0.70 per share) and proposed a 2:1 bonus share issue, subject to shareholder approval at the 39th AGM convened on June 30, 2026. The company increased its authorized share capital from ₹10 crore to ₹50 crore to facilitate future growth and the bonus issue. During FY26, Fredun raised capital through a preferential issue of 6,44,360 equity shares at ₹1,250 per share and issued 5,51,600 share warrants convertible to equity shares.
Expansion & Subsidiaries
The company expanded through new subsidiaries including Fredun Retail Private Limited (wholly-owned, incorporated January 2025) and One Pet Stop Private Limited (acquired March 2025). Property, Plant & Equipment increased 124% to ₹11,762.87 lakhs, with lotion capacity expanding to 167,000 bottles per day. The company maintained a net debt to equity ratio of 1.05 (standalone) and 0.57 (consolidated), with floating rate borrowings of ₹22,203.05 lakhs.
AGM Agenda & Governance
The 39th AGM agenda includes adoption of financial statements, dividend declaration, re-appointment of Dr. Mrs. D. N. Medhora as Whole-Time Director, and special business items including increased borrowing limits to ₹600 crore, approval of related party transactions up to ₹1 crore per transaction, and ratification of cost auditor remuneration. Shareholders can participate remotely via video conference with e-voting available through NSDL from June 27-29, 2026.
Risk Management & Compliance
The company actively managed foreign exchange risk (net exposure ₹20,193.05 lakhs), credit risk, and liquidity risk. Auditors issued an unmodified opinion on financial statements despite noting delays in transferring unclaimed dividends for FY 2015-16 to 2017-18 to IEPF. The company spent ₹44.82 lakhs on CSR activities, achieving 100% compliance with the 2% requirement, focusing on hunger eradication, education, healthcare, and environmental sustainability.
Related Party Transactions
Key management personnel transactions included remuneration of ₹54 lakhs to Mr. Fredun Nariman Medhora (Managing Director & CFO) and ₹12 lakhs to Dr. Mrs. Daulat Nariman Medhora (Joint Managing Director). Significant related party sales included ₹1,968.99 lakhs to Fredna Dental Systems and ₹646.10 lakhs to Innovus Healthcare L.L.C. Outstanding director loans totaled ₹1,258.07 lakhs to Mr. Fredun N. Medhora.
Outlook & Implications
The combination of strong financial performance, dividend distribution, bonus issue, and expanded borrowing capacity positions Fredun Pharmaceuticals for continued growth in the pharmaceutical sector, supported by its recent expansion into retail subsidiaries and increased manufacturing capacity.